LEADER 01287nam  2200385Ka 450 
001 9910696633503321
005 20080612151648.0
035   $a(CKB)5470000002380528
035   $a(OCoLC)231761125
035   $a(EXLCZ)995470000002380528
100   $a20080612d2003      ua             0
101 0 $aeng
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aNew drug development$b[electronic resource] $eestimating entry from human clinical trials /$fChristopher P. Adams & Van V. Brantner
210  1$a[Washington, D.C.] :$cBureau of Economics, Federal Trade Commission,$d[2003]
215   $a24 pages $cdigital, PDF file
225 1 $aWorking paper ;$vno. 262
300   $aTitle from title screen (viewed on June 12, 2008).
300   $a"July 7, 2003."
517   $aNew drug development 
606   $aDrug development
606   $aClinical trials
615  0$aDrug development.
615  0$aClinical trials.
700   $aAdams$b Christopher P$01387614
701   $aBrantner$b Van V$01411284
712 02$aUnited States.$bFederal Trade Commission.$bBureau of Economics.
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910696633503321
996   $aNew drug development$93502136
997   $aUNINA